Veranstaltungskalender
Raphael Lutz, Druck Ausrüstung Kraft Premium GmbH, Andreas Trojan(Immunologie-Zentrum Zürich), Christian Michel(Fund for Scientific Research), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Hartmut Link(Medizinische Hochschule Hannover), Ann-Katrin Seidel, Christopher Soll(GZO Spital Wetzikon), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Andreas Stephan Lübbe, Sylvie Lorenzen, Kia Homayounfar, Eugen Ruckhäberle, Andreas Leischker, Miklos Pless, Paul Graf La Rosée, Georg Heß(Johannes Gutenberg University Mainz), Jacques Gubler, Caroline Hochuli
Cited by 0
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879